Recent Analysts’ Ratings Updates for Moderna (MRNA)

A number of firms have modified their ratings and price targets on shares of Moderna (NASDAQ: MRNA) recently:

• 9/9/2026 – Moderna had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 9/3/2026 – Moderna was given a new $81.00 price target by UBS Group AG.
• 9/3/2026 – Moderna was downgraded by UBS Group AG from “hold” to “sell”.
• 9/3/2026 – Moderna was downgraded by Rothschild & Co Redburn from “neutral” to “sell”. They now have a $81.00 price target on the stock, up from $40.00.
• 8/28/2026 – Moderna was upgraded by CLSA to “outperform”.
• 8/28/2026 – Moderna is now covered by Deutsche Bank Aktiengesellschaft. They set a “hold” rating on the stock.
• 8/28/2026 – Moderna is now covered by William Blair. They set an “outperform” rating on the stock.
• 8/28/2026 – Moderna was upgraded by Bradesco Corretora to “outperform”.
• 8/28/2026 – Moderna was upgraded by Argus from “hold” to “buy”. They now have a $180.00 price target on the stock.
• 8/25/2026 – Moderna was upgraded by Wolfe Research from “underperform” to “peer perform”.
• 8/24/2026 – Moderna had its price target raised by Barclays PLC from $48.00 to $125.00. They now have an “equal weight” rating on the stock.
• 8/21/2026 – Moderna had its price target raised by JPMorgan Chase & Co. from $40.00 to $77.00. They now have an “underweight” rating on the stock.
• 8/20/2026 – Moderna had its price target raised by UBS Group AG from $50.00 to $150.00. They now have a “neutral” rating on the stock.
• 8/20/2026 – Moderna had its price target raised by Morgan Stanley from $39.00 to $89.00. They now have an “equal weight” rating on the stock.
• 8/19/2026 – Moderna had its “neutral” rating reaffirmed by Morgan Stanley.
• 8/19/2026 – Moderna had its price target raised by The Goldman Sachs Group, Inc. from $67.00 to $120.00. They now have a “neutral” rating on the stock.
• 8/19/2026 – Moderna had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a $130.00 price target on the stock.
• 8/19/2026 – Moderna was given a new $135.00 price target by Loop Capital.
• 8/19/2026 – Moderna had its “buy” rating reaffirmed by Brookline Capital Markets.
• 8/19/2026 – Moderna had its “hold” rating reaffirmed by Jefferies Financial Group Inc..
• 8/19/2026 – Moderna was upgraded by Bank of America Corporation from “underperform” to “neutral”.
• 8/19/2026 – Moderna was upgraded by William Blair from “market perform” to “outperform”.
• 8/3/2026 – Moderna had its “overweight” rating reaffirmed by UBS Group AG.
• 8/3/2026 – Moderna had its “overweight” rating reaffirmed by Piper Sandler.
• 8/3/2026 – Moderna had its price target raised by Citigroup Inc. from $41.00 to $60.00. They now have a “neutral” rating on the stock.
• 7/21/2026 – Moderna had its price target raised by The Goldman Sachs Group, Inc. from $49.00 to $67.00. They now have a “neutral” rating on the stock.
• 7/20/2026 – Moderna had its “underperform” rating reaffirmed by Wolfe Research. They now have a $25.00 price target on the stock.

Insider Activity at Moderna

In other Moderna news, insider Shannon Klinger sold 3,471 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider directly owned 74,129 shares in the company, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James M. Mock sold 34,836 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer owned 59,375 shares of the company’s stock, valued at $7,985,343.75. This represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.80% of the company’s stock.

Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.

The company’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.